Annual Accounts Payable
$6.43 M
+$2.54 M+65.32%
31 December 2023
Summary:
Galectin Therapeutics annual accounts payable is currently $6.43 million, with the most recent change of +$2.54 million (+65.32%) on 31 December 2023. During the last 3 years, it has risen by +$5.14 million (+397.76%). GALT annual accounts payable is now at all-time high.GALT Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$2.79 M
-$903.00 K-24.42%
30 September 2024
Summary:
Galectin Therapeutics quarterly accounts payable is currently $2.79 million, with the most recent change of -$903.00 thousand (-24.42%) on 30 September 2024. Over the past year, it has increased by +$114.00 thousand (+4.25%). GALT quarterly accounts payable is now -56.54% below its all-time high of $6.43 million, reached on 31 December 2023.GALT Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +65.3% | +4.3% |
| 3 y3 years | +397.8% | +45.8% |
| 5 y5 years | +2065.3% | +689.5% |
GALT Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +397.8% | -56.5% | +54.9% |
| 5 y | 5 years | at high | +2065.3% | -56.5% | +1256.8% |
| alltime | all time | at high | +5044.8% | -56.5% | +2667.3% |
Galectin Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $2.79 M(-24.4%) |
| June 2024 | - | $3.70 M(-2.6%) |
| Mar 2024 | - | $3.80 M(-41.0%) |
| Dec 2023 | $6.43 M(+65.3%) | $6.43 M(+139.9%) |
| Sept 2023 | - | $2.68 M(+35.7%) |
| June 2023 | - | $1.98 M(-22.6%) |
| Mar 2023 | - | $2.55 M(-34.4%) |
| Dec 2022 | $3.89 M(+115.5%) | $3.89 M(+65.4%) |
| Sept 2022 | - | $2.35 M(-20.6%) |
| June 2022 | - | $2.96 M(+55.5%) |
| Mar 2022 | - | $1.91 M(+5.6%) |
| Dec 2021 | $1.80 M(+39.7%) | $1.80 M(-5.8%) |
| Sept 2021 | - | $1.92 M(+107.5%) |
| June 2021 | - | $924.00 K(+141.9%) |
| Mar 2021 | - | $382.00 K(-70.4%) |
| Dec 2020 | $1.29 M(-22.2%) | $1.29 M(+87.0%) |
| Sept 2020 | - | $691.00 K(+235.4%) |
| June 2020 | - | $206.00 K(-68.8%) |
| Mar 2020 | - | $660.00 K(-60.3%) |
| Dec 2019 | $1.66 M(+459.3%) | $1.66 M(+369.2%) |
| Sept 2019 | - | $354.00 K(-10.6%) |
| June 2019 | - | $396.00 K(-11.6%) |
| Mar 2019 | - | $448.00 K(+50.8%) |
| Dec 2018 | $297.00 K(-51.2%) | $297.00 K(+73.7%) |
| Sept 2018 | - | $171.00 K(-22.3%) |
| June 2018 | - | $220.00 K(-80.9%) |
| Mar 2018 | - | $1.15 M(+89.3%) |
| Dec 2017 | $608.00 K(-33.2%) | $608.00 K(+266.3%) |
| Sept 2017 | - | $166.00 K(-58.4%) |
| June 2017 | - | $399.00 K(-70.4%) |
| Mar 2017 | - | $1.35 M(+47.9%) |
| Dec 2016 | $910.00 K(+103.1%) | $910.00 K(+39.6%) |
| Sept 2016 | - | $652.00 K(-30.0%) |
| June 2016 | - | $932.00 K(-28.9%) |
| Mar 2016 | - | $1.31 M(+192.6%) |
| Dec 2015 | $448.00 K(-50.6%) | $448.00 K(-51.8%) |
| Sept 2015 | - | $929.00 K(+19.9%) |
| June 2015 | - | $775.00 K(-15.9%) |
| Mar 2015 | - | $922.00 K(+1.8%) |
| Dec 2014 | $906.00 K(+18.9%) | $906.00 K(+8.1%) |
| Sept 2014 | - | $838.00 K(+26.0%) |
| June 2014 | - | $665.00 K(+36.8%) |
| Mar 2014 | - | $486.00 K(-36.2%) |
| Dec 2013 | $762.00 K(+91.9%) | $762.00 K(+102.1%) |
| Sept 2013 | - | $377.00 K(+32.3%) |
| June 2013 | - | $285.00 K(-9.8%) |
| Mar 2013 | - | $316.00 K(-20.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $397.00 K(+3.4%) | $397.00 K(+55.1%) |
| Sept 2012 | - | $256.00 K(+4.1%) |
| June 2012 | - | $246.00 K(-63.2%) |
| Mar 2012 | - | $669.00 K(+74.2%) |
| Dec 2011 | $384.00 K(+207.2%) | $384.00 K(+93.9%) |
| Sept 2011 | - | $198.00 K(+53.5%) |
| June 2011 | - | $129.00 K(-29.1%) |
| Mar 2011 | - | $182.00 K(+45.6%) |
| Dec 2010 | $125.00 K(-43.4%) | $125.00 K(-33.9%) |
| Sept 2010 | - | $189.00 K(+87.1%) |
| June 2010 | - | $101.00 K(-40.6%) |
| Mar 2010 | - | $170.00 K(-23.1%) |
| Dec 2009 | $221.00 K(-50.6%) | $221.00 K(-55.4%) |
| Sept 2009 | - | $496.00 K(-34.5%) |
| June 2009 | - | $757.00 K(-6.0%) |
| Mar 2009 | - | $805.00 K(+80.1%) |
| Dec 2008 | $447.00 K(-25.6%) | $447.00 K(+179.4%) |
| Sept 2008 | - | $160.00 K(-32.8%) |
| June 2008 | - | $238.00 K(-48.6%) |
| Mar 2008 | - | $463.00 K(-23.0%) |
| Dec 2007 | $601.00 K(+76.8%) | $601.00 K(+4.9%) |
| Sept 2007 | - | $573.00 K(+33.9%) |
| June 2007 | - | $428.00 K(-26.7%) |
| Mar 2007 | - | $584.00 K(+71.8%) |
| Dec 2006 | $340.00 K(+15.3%) | $340.00 K(-18.3%) |
| Sept 2006 | - | $416.00 K(+70.5%) |
| June 2006 | - | $244.00 K(-52.9%) |
| Mar 2006 | - | $518.00 K(+75.6%) |
| Dec 2005 | $295.00 K(+43.2%) | $295.00 K(+81.0%) |
| Sept 2005 | - | $163.00 K(-34.5%) |
| June 2005 | - | $249.00 K(-33.2%) |
| Mar 2005 | - | $373.00 K(+81.1%) |
| Dec 2004 | $206.00 K(+24.1%) | $206.00 K(-39.4%) |
| Sept 2004 | - | $340.00 K(+217.8%) |
| June 2004 | - | $107.00 K(-84.4%) |
| Mar 2004 | - | $686.70 K(+313.7%) |
| Dec 2003 | $166.00 K(-45.2%) | $166.00 K(-51.4%) |
| Sept 2003 | - | $341.60 K(-6.2%) |
| June 2003 | - | $364.20 K(+44.8%) |
| Mar 2003 | - | $251.60 K(-16.9%) |
| Dec 2002 | $302.90 K(+28.2%) | $302.90 K(+32.1%) |
| Sept 2002 | - | $229.30 K(-58.6%) |
| June 2002 | - | $554.50 K(+169.8%) |
| Mar 2002 | - | $205.50 K(-13.0%) |
| Dec 2001 | $236.20 K | $236.20 K(-18.6%) |
| Sept 2001 | - | $290.30 K(+30.5%) |
| June 2001 | - | $222.40 K |
FAQ
- What is Galectin Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Galectin Therapeutics?
- What is Galectin Therapeutics annual accounts payable year-on-year change?
- What is Galectin Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly accounts payable year-on-year change?
What is Galectin Therapeutics annual accounts payable?
The current annual accounts payable of GALT is $6.43 M
What is the all time high annual accounts payable for Galectin Therapeutics?
Galectin Therapeutics all-time high annual accounts payable is $6.43 M
What is Galectin Therapeutics annual accounts payable year-on-year change?
Over the past year, GALT annual accounts payable has changed by +$2.54 M (+65.32%)
What is Galectin Therapeutics quarterly accounts payable?
The current quarterly accounts payable of GALT is $2.79 M
What is the all time high quarterly accounts payable for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly accounts payable is $6.43 M
What is Galectin Therapeutics quarterly accounts payable year-on-year change?
Over the past year, GALT quarterly accounts payable has changed by +$114.00 K (+4.25%)